Atlantic Bluefish Fishery Management Plan in late 2017. A notice of intent to develop an environmental impact statement for this action was published in June 2018. However, following a second round of scoping meetings in February and March 2020, it has been determined that the range of proposed alternatives included in this amendment are not expected to have significant impacts on the fishery or affected environment. Therefore, NMFS is withdrawing the notice of intent and will continue development of an environmental assessment instead.


SUPPLEMENTARY INFORMATION: In December 2017, the Council initiated a comprehensive amendment to the Bluefish Fishery Management Plan (FMP) to review and update the goals and objectives of this FMP, as well as reevaluate quota allocation and transfer provisions between sectors and states, in light of changing fishery conditions and stakeholder priorities. The Council published a notice of intent to develop an environmental impact statement for this amendment in accordance with the National Environmental Policy Act to analyze the impacts of any proposed management measures (83 FR 26267; June 6, 2018), and held a series of scoping hearings with the Atlantic States Marine Fisheries Commission’s Bluefish Board in June and July of 2018. Following this round of scoping, development on the amendment was put on hold until the results of the August 2019 operational stock assessment were available that incorporated revised Marine Recreational Information Program data into its model. The 2019 assessment determined that the bluefish stock is now overfished although overfishing is not occurring, and at its December 2019 meeting, the Council decided to add the rebuilding plan to Amendment 7. The Council must develop and implement a rebuilding plan within 2 years of notification that a stock is overfished, by the end of November 2021. Following a second round of scoping hearings in February and March 2020, the Council and NMFS have determined that the range of proposed alternatives included in this amendment are not expected to have significant impacts on the fishery or affected environment and that an environmental assessment will be developed. Therefore, this notice announces the Council’s withdrawal of the Notice of Intent to Prepare an Environmental Impact Statement for Amendment 7 to the Bluefish FMP. Development of the amendment will continue with an environmental assessment instead.

Authority: 16 U.S.C. 1801 et seq.

Jennifer M. Wallace, Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service.

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[FR Doc. 2020–20200 Filed 10–2–20; 8:45 am]

BILLING CODE 3510–22–P

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[FR Doc. 2020–21968 Filed 10–2–20; 8:45 am]

BILLING CODE 3510–1630–P

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[FR Doc. 2020–20004 Filed 10–2–20; 8:45 am]

BILLING CODE 3510–22–P

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[FR Doc. 2020–20009 Filed 10–2–20; 8:45 am]

BILLING CODE 3510–22–P

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[FR Doc. 2020–21963 Filed 10–2–20; 8:45 am]

BILLING CODE 3510–1630–P

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[FR Doc. 2020–20008 Filed 10–2–20; 8:45 am]

BILLING CODE 3510–1630–P

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[FR Doc. 2020–21967 Filed 10–2–20; 8:45 am]

BILLING CODE 3510–1630–P

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[FR Doc. 2020–21965 Filed 10–2–20; 8:45 am]

BILLING CODE 3510–1630–P

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[FR Doc. 2020–21962 Filed 10–2–20; 8:45 am]

BILLING CODE 3510–1630–P
35 U.S.C. 156(d)(5) for a second interim extension of the term of the '699 patent. The '699 patent claims a method of using a veterinary biological product in the cancer immunotherapy treatment known by the tradename ECI® (ELIAS Cancer Immunotherapy). The application for interim patent term extension indicates that an application for a license for the veterinary biological product was submitted under the Virus-Serum-Toxin Act and is currently undergoing regulatory review by the United States Department of Agriculture, Center for Veterinary Biologies.

Review of the interim patent term extension application indicates that, except for permission to market or use the product commercially, the '699 patent would be eligible for an extension of the patent term under 35 U.S.C. 156. Because it appears the approval phase of the regulatory review period will continue beyond the extended expiration date of the '699 patent, i.e., October 5, 2020, further interim extension of the patent term under 35 U.S.C. 156(d)(5) is appropriate.

A second interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 6,406,699 is granted for a period of one year from the extended expiration date of the '699 patent.

Robert Bahr,
Deputy Commissioner for Patent Examination Policy, United States Patent and Trademark Office.

[FR Doc. 2020–21966 Filed 10–2–20; 8:45 am] 
BILLING CODE 3510–16–P

SUPPLEMENTARY INFORMATION: 35 U.S.C. 156 generally provides that the term of a patent may be extended for a period of up to five years, if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review. 35 U.S.C. 156(d)(5) generally provides that the term of such a patent may be extended for no more than five interim periods of up to one year each, if the approval phase of the regulatory review period is reasonably expected to extend beyond the expiration date of the patent.

On July 14, 2020, Correvio International Sàrl, the owner of record of the '879 patent, timely filed an application under 35 U.S.C. 156(d)(5) for an interim extension of the term of the '879 patent. The '879 patent claims a method of using the product vernakalant hydrochloride. The application for interim patent term extension indicates that New Drug Application No. 22–034 for vernakalant hydrochloride was submitted to the Food and Drug Administration (FDA) on December 19, 2006, and that the FDA’s review thereof is ongoing.

Review of the interim patent term extension application indicates that, except for permission to market or use the product commercially, the '879 patent would be eligible for an extension of the patent term under 35 U.S.C. 156. Because it appears the approval phase of the regulatory review period will continue beyond the original expiration date of the patent, i.e., October 6, 2020, interim extension of the '879 patent’s term under 35 U.S.C. 156(d)(5) is appropriate.

An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 7,524,879 is granted for a period of one year from the original expiration date of the '879 patent.

Robert Bahr,
Deputy Commissioner for Patent Examination Policy, United States Patent and Trademark Office.

[FR Doc. 2020–21966 Filed 10–2–20; 8:45 am] 
BILLING CODE 3510–16–P

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[Docket No. PTO–P–2020–0048]

Grant of Interim Extension of the Term of U.S. Patent No. 7,524,879; Vernakalant Hydrochloride

AGENCY: United States Patent and Trademark Office, Department of Commerce.

ACTION: Notice of interim patent term extension.


FOR FURTHER INFORMATION CONTACT: Raul Tamayo, Senior Legal Advisor, Office of Patent Legal Administration, by telephone at 571–272–7728 or by email to raul.tamayo@uspto.gov.

SUPPLEMENTARY INFORMATION: 35 U.S.C. 156 generally provides that the term of a patent may be extended for a period of up to five years, if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review. 35 U.S.C. 156(d)(5) generally provides that the term of such a patent may be extended for no more than five interim periods of up to one year each, if the approval phase of the regulatory review period is reasonably expected to extend beyond the expiration date of the patent.

On July 14, 2020, Correvio International Sàrl, the owner of record of the '053 patent, timely filed an application under 35 U.S.C. 156(d)(5) for an interim extension of the term of the '053 patent. The '053 patent claims the product vernakalant hydrochloride. The application for interim patent term extension indicates that New Drug Application No. 22–034 for vernakalant hydrochloride was submitted to the Food and Drug Administration (FDA) on December 19, 2006, and that the FDA’s review thereof is ongoing.

Review of the interim patent term extension application indicates that, except for permission to market or use the product commercially, the '053 patent would be eligible for an extension of the patent term under 35 U.S.C. 156. Because it appears the approval phase of the regulatory review period will continue beyond the original expiration date of the patent, i.e., October 6, 2020, interim extension of the '053 patent’s term under 35 U.S.C. 156(d)(5) is appropriate.

An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 7,524,879 is granted for a period of one year from the original expiration date of the '879 patent.

Robert Bahr,
Deputy Commissioner for Patent Examination Policy, United States Patent and Trademark Office.

[FR Doc. 2020–21966 Filed 10–2–20; 8:45 am] 
BILLING CODE 3510–16–P